In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8⁺ T cell responses
J. Clin. Invest. Christoph Esslinger, et al. 111:1673 doi:10.1172/JCI17098 [Go to this article.]

Figure 4
Induction of a Melan-A–specific CD8⁺ T cell response in HLA-A*0201/K^b transgenic mice vaccinated by administration of lentivector encoding the Melan-A CTL epitope ELA_26–35. As controls, a lentivector expressing an irrelevant CTL epitope and the administration of ELA_26–35 peptide in combination with CpG and IFA were used. (a) Phenotypic characterization of the peak of immune response (day 14 for lentivector vaccination and day 7 for peptide/CpG/adjuvant vaccination) of individual mice. Melan-A–specific cells among total PBLs are shown in the first row of panels; the percentage of tetramer-positive cells is indicated. The proportion of activated CD8⁺ cells and the percentages of Melan-A–specific cells contained therein and in total CD8⁺ cells are displayed in histograms. (b) Proportion of Melan-A–specific CD8⁺ cells at peak response of all individual mice tested. (Dashed lines and x = average, n = number of mice tested per condition).